Benefits
BPH Symptom Support
AGEprost designed to address BPH symptoms — urinary frequency, urgency, weak flow, nocturia.
Urinary Flow Support
Prostate enlargement compresses urethra; AGEprost targets urinary flow symptoms.
Prostate Health for Aging Men
BPH affects 50%+ of men by age 50, 80% by age 80. AGEprost positioned as part of healthy aging prostate care.
Standardized Formulation
Saanroo proprietary standardization ensures consistent active compound delivery.
Mechanism of action
Prostate-Specific Activity
AGEprost designed for prostate tissue effects — specific mechanism per Saanroo formulation.
Urinary Symptom Mechanisms
Likely involves bladder/urethra effects, prostate tissue support, possibly inflammatory pathway modulation.
Complementary to Standard BPH Care
Standard BPH care includes lifestyle, medications (alpha-blockers, 5-alpha-reductase inhibitors), AGEprost as supplement adjunct.
Clinical trials
Clinical studies of AGEprost in men with BPH and prostate health concerns.
Men with BPH symptoms.
Improvements in BPH-related symptoms and urinary flow parameters.
About this ingredient
AGEPROST is a PROSTATE HEALTH INGREDIENT developed by SAANROO (formerly Gencor Pacific) — designed for BENIGN PROSTATIC HYPERPLASIA (BPH) and prostate health support. BPH BACKGROUND: progressive enlargement of prostate gland with age; symptoms result from urethral compression — urinary frequency, urgency, weak stream, nocturia, incomplete emptying.
EVIDENCE-BASED USES: (1) BPH SYMPTOM SUPPORT; (2) Urinary flow improvement; (3) Prostate health for aging men; (4) Adjunct to comprehensive BPH care.
CRITICAL CAUTIONS: (1) MEDICAL EVALUATION FIRST — urinary symptoms warrant medical evaluation to rule out prostate cancer, urinary retention, kidney impact; (2) PROSTATE CANCER — symptoms can overlap with BPH; PSA testing appropriate; (3) MEDICATION INTERACTIONS — alpha-blockers, 5-alpha-reductase inhibitors are standard BPH medications; consult prescriber; (4) DOSE — per Saanroo specification; (5) DURATION — BPH symptom effects build over 8-12 weeks; (6) AGEPROST vs SAW PALMETTO vs BETA-SITOSTEROL — multiple natural prostate support options; choice based on clinical context; (7) WATCHFUL WAITING — early BPH may not require treatment; lifestyle measures foundational; (8) ACUTE URINARY RETENTION — emergency requiring catheterization; not addressed by supplements; (9) HEALTHY AGING APPROACH — comprehensive aging male health includes cardiovascular, metabolic, exercise, weight, prostate health; (10) ELDERLY POPULATIONS — most relevant target demographic.